Advanced Accelerator Applications is working on marrying targeted drug design with nuclear medicine technology to develop drugs that can recognize and treat diseases.

A Cell & Gene production unit staffed by a highly trained team at Novartis will soon begin operating in Stein, Switzerland.

The recently appointed leader of the Novartis’ digital research and development platform data42 is a strong believer that data and digital technologies will change the path of medical science.

Two scientists from Basel are trying to shed light on why myopia is impacting more and more people.

With Nerve Live, Novartis is harnessing the power of data for the benefit of patients.

Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42.

An interview with Thierry Diagana, Head of the Novartis Institute for Tropical Diseases.